Potential targeted therapy for liver fluke associated cholangiocarcinoma
Potential targeted therapy for liver fluke associated cholangiocarcinoma
复制标题
DOI：
10.1002/jhbp.65
复制
发表时间：
2014-06-01
影响因子：
3
通讯作者：
Wongkham, Sopit
中科院分区：
文献类型：
--
作者：
Vaeteewoottacharn, Kulthida;Seubwai, Wunchana;Wongkham, Sopit
胆管树癌或胆管癌（CCA）是一种不常见的肝癌亚型，预后极差。缺乏特定症状和早期诊断标志物的可用性导致了 CCA 的晚期诊断。手术治疗是金标准选择，但适合的患者很少，而且手术后局部复发率很高。全身化疗的益处有限；因此，需要更好的治疗选择。病因、解剖位置和病理学的差异使得很难将所有 CCA 亚型概括为单一治疗方案。在此，我们回顾了通过多种方法鉴定的分子谱分析的独特性，例如基因表达的系列分析、外显子组测序、转录组学/蛋白质组学谱、蛋白激酶谱等，这些方法为治疗肝吸虫相关的CCA提供了机会。本综述建议使用抗炎药、免疫调节剂/免疫抑制剂、表皮生长因子受体或血小板衍生生长因子受体抑制剂、多靶点酪氨酸激酶抑制剂、IL6拮抗剂、核因子-κB抑制剂、组蛋白调节剂、蛋白酶体抑制剂以及各种研究方法建议的特异性抑制剂，如MetAP2抑制剂、1,25(OH)(2)D-3和环孢菌素A来治疗该特定疾病。 CCA 亚型。这可能为 CCA 患者提供替代治疗选择；然而，需要在这个特定的 CCA 组中进行临床试验。
Biliary tree cancer or cholangiocarcinoma (CCA) is an unusual subtype of liver cancer with exceptionally poor prognosis. Lack of specific symptoms and availability of early diagnostic markers account for late diagnosis of CCA. Surgical treatment is a gold standard choice but few patients are candidates and local recurrence after surgery is high. Benefit of systemic chemotherapy is limited; hence, better treatment options are required. The differences in etiology, anatomical positions and pathology make it difficult to generalize all CCA subtypes for a single treatment regimen. Herein, we review the uniqueness of molecular profiling identified by multiple approaches, for example, serial analysis of gene expression, exome sequencing, transcriptomics/proteomics profiles, protein kinase profile, etc., that provide the opportunity for treatment of liver fluke-associated CCA. Anti-inflammatory, immunomodulator/immunosuppressor, epidermal growth factor receptor or platelet-derived growth factor receptor inhibitors, multi-targeted tyrosine kinase inhibitor, IL6 antagonist, nuclear factor-kappa B inhibitor, histone modulator, proteasome inhibitor as well as specific inhibitors suggested from various study approaches, such as MetAP2 inhibitor, 1,25(OH)(2)D-3 and cyclosporine A are suggested in this review for the treatments of this specific CCA subtype. This might provide an alternative treatment option for CCA patients; however, clinical trials in this specific CCA group are required.